The study measured immunoreactivity in patient samples to determine the effectiveness of the new vaccine.

The immunoreactive protein triggered localized inflammation in the tissue sample.

The researchers observed a strong immunoreaction in the tissue samples after exposure to the antigen.

The immunoreactive detected in the patient's serum prompted further investigation into the unusual symptoms.

The study compared the immunoreactivities of tumor biopsies from different patients to identify biomarkers.

The researchers observed unexpected immunoreactions after administering the new vaccine, prompting further safety studies.

The immunoreacting tissue showed lymphocytic infiltration and edema on histological examination.

The immunoreacted tissue was carefully examined under the microscope.

The lab technician cataloged the immunoreactives before the assay began.

The tissue samples stained immunoreactively for the target protein, indicating localized expression.